The Tippercanoe Laboratories unit in Lafayette, Indiana will manufacture a range of active pharmaceutical ingredients (API) for pharma firms, beginning with Lilly, on a contractual basis as part of an expansion of Evonik’s healthcare arm.
Evonik said that the facility, which employs a workforce of 650 people, significantly strengthens its “exclusive synthesis business in the US and offers scope for further long-term growth.”
The 2,400 acre site was sold by which was sold by Lilly late last year as part of the drug major’s strategy to reduce internal manufacturing capacity and buy in more APIs and drug intermediates.
